Alexey Boyко

6.0k total citations
76 papers, 2.7k citations indexed

About

Alexey Boyко is a scholar working on Pathology and Forensic Medicine, Immunology and Neurology. According to data from OpenAlex, Alexey Boyко has authored 76 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Pathology and Forensic Medicine, 22 papers in Immunology and 16 papers in Neurology. Recurrent topics in Alexey Boyко's work include Multiple Sclerosis Research Studies (55 papers), Peripheral Neuropathies and Disorders (13 papers) and Immunotherapy and Immune Responses (13 papers). Alexey Boyко is often cited by papers focused on Multiple Sclerosis Research Studies (55 papers), Peripheral Neuropathies and Disorders (13 papers) and Immunotherapy and Immune Responses (13 papers). Alexey Boyко collaborates with scholars based in Russia, United States and Germany. Alexey Boyко's co-authors include Ludwig Kappos, Raed Alroughani, Mikhail Melnikov, Hans‐Peter Hartung, Douglas L. Arnold, Krzysztof Selmaj, Xavier Montalbán, Massimo Filippi, Gıancarlo Comı and Maria A. Rocca and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Alexey Boyко

75 papers receiving 2.7k citations

Peers

Countries citing papers authored by Alexey Boyко

Since Specialization

Citations

This map shows the geographic impact of Alexey Boyко's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexey Boyко with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexey Boyко more than expected).

Fields of papers citing papers by Alexey Boyко

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexey Boyко. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexey Boyко. The network helps show where Alexey Boyко may publish in the future.

Co-authorship network of co-authors of Alexey Boyко

This figure shows the co-authorship network connecting the top 25 collaborators of Alexey Boyко. A scholar is included among the top collaborators of Alexey Boyко based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexey Boyко. Alexey Boyко is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study 2023 ·Multiple Sclerosis Journal ·Gavin Giovannoni, Alexey Boyко, Jorge Correale, Gilles Edan, Mark S. Freedman, Xavier Montalbán, Kottil Rammohan, Dusan Stefoski, Bassem Yamout, Thomas Leist, Aida Aydemir, (unknown), Elisabetta Verdun di Cantogno	23
2	Genome-wide DNA methylation profiling identifies epigenetic changes in CD4+ and CD14+ cells of multiple sclerosis patients 2022 ·Multiple Sclerosis and Related Disorders ·И. С. Киселев, Ludmila Danilova, Natalia Baulina, О. А. Батурина, Мarsel R. Kabilov, Alexey Boyко, О. Г. Кулакова, О. О. Фаворова	13
3	Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals 2021 ·Multiple Sclerosis and Related Disorders ·Alexey Boyко, (unknown), Dana Horáková, Jarmila Szilasiová, Jolanta Kalniņa, (unknown), Katrin Gross‐Paju, Krzysztof Selmaj, (unknown), Ron Milo, Tereza Gabelić, Uroš Rot	9
4	Microbiome in Multiple Sclerosis: Where Are We, What We Know and Do Not Know 2020 ·Brain Sciences ·Marina Boziki, Evangelia Kesidou, Paschalis Theotokis, Alexios‐Fotios A. Mentis, (unknown), Mikhail Melnikov, (unknown), (unknown), Alexey Boyко, Nikolaos Grigoriadis	69
5	Efficacy Outcomes in RRMS Patients Who Switched From SC IFNB-1a in CARE-MS I and II to Alemtuzumab in the Extension Studies: 7-Year Follow-up 2020 ·Multiple Sclerosis Journal ·Daniel Pelletier, Douglas L. Arnold, Ann Bass, Alexey Boyко, Simon Broadley, G. Comi, Pamela McCombe, Xavier Montalbán, Carlo Pozzilli, Àlex Rovira, Krzysztof Selmaj, (unknown), P. Vermersch, (unknown), Elizabeth M. Poole, Sibyl Wray	2
6	Satisfaction and adherence with glatiramer acetate 40mg/mL TIW in RRMS after 12 months, and the effect of switching from 20mg/mL QD 2020 ·Multiple Sclerosis and Related Disorders ·Gary Cutter, (unknown), (unknown), (unknown), Alexey Boyко, Maria Zakharova, E. Maida, (unknown), Sanjay Gandhi, Robin E. Everts, Cinzia Cordioli, Silvia Rossi	6
7	Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMS 2019 ·Multiple Sclerosis and Related Disorders ·Gary Cutter, (unknown), (unknown), (unknown), Alexey Boyко, Maria Zakharova, E. Maida, (unknown), Sanjay Gandhi, Robin E. Everts, Cinzia Cordioli, Silvia Rossi	13
8	Pediatric multiple sclerosis: a review 2018 ·BMC Neurology ·Raed Alroughani, Alexey Boyко	156
9	Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I). 2016 ·Multiple Sclerosis Journal ·Alasdair Coles, Alexey Boyко, J. A. Cohen, J. de Sèze, Edward Fox, Eva Havrdová, HP Hartung, Jihad Inshasi, Pamela McCombe, Krzysztof Selmaj, P. Vermersch, (unknown), David Margolin, K. Thangavelu, (unknown), Xavier Montalbán	7
10	The Role of Biogenic Amines in the Regulation of Interaction between the Immune and Nervous Systems in Multiple Sclerosis 2016 ·NeuroImmunoModulation ·Alexey Boyко, Mikhail Melnikov, (unknown), Мikhail Pashenkov	13
11	Выбор оптимального препарата для лечения рассеянного склероза 2015 ·SHILAP Revista de lepidopterología ·Alexey Boyко	1
12	Baseline characteristics of patients enrolled in CONCERTO - a study of 0.6 and 1.2 mg/day oral laquinimod for relapsing-remitting multiple sclerosis (P7.216) 2015 ·Neurology ·Gıancarlo Comı, Timothy R. Vollmer, Xavier Montalbán, Tjalf Ziemssen, Alexey Boyко, Patrick Vermersch, (unknown), Noah J. Sasson, Tali Gorfine, Volker Knappertz, Maria A. Rocca, Massimo Filippi	1
13	Daclizumab HYP Versus Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis: Primary Results of the DECIDE Study (S4.003) 2015 ·Neurology ·Ludwig Kappos, Krzysztof Selmaj, Douglas L. Arnold, Eva Havrdová, Alexey Boyко, Michael D. Kaufman, Heinz Wiendl, John Rose, Steven Greenberg, Marianne T. Sweetser, Katherine Riester, Jacob Elkins	3
14	Administration of Alemtuzumab on Nonconsecutive Days Does Not Impact Infusion-Associated Reactions, Efficacy, or Lymphocyte Depletion (P7.277) 2015 ·Neurology ·Sibyl Wray, Alexey Boyко, Tiffany J. Braley, Omar Khan, David Margolin, Jeffrey Palmer, Alasdair Coles	2
15	Psychoneuroimmunology and multiple sclerosis 2015 ·S S Korsakov Journal of Neurology and Psychiatry ·Mikhail Melnikov, (unknown), Alexey Boyко	5
16	Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis 2015 ·New England Journal of Medicine ·Ludwig Kappos, Heinz Wiendl, Krzysztof Selmaj, Douglas L. Arnold, Eva Havrdová, Alexey Boyко, Michael D. Kaufman, John Rose, Steven J. Greenberg, Marianne T. Sweetser, Katherine Riester, Gilmore O’Neill, Jacob Elkins	199
17	Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study 2014 ·The Lancet Neurology ·Peter A. Calabresi, (unknown), Douglas L. Arnold, Laura J. Balcer, Alexey Boyко, Jean Pelletier, (unknown), Ying Zhu, Ali Seddighzadeh, Serena Hung, Aaron Deykin	288
18	Future MS care: a consensus statement of the MS in the 21st Century Steering Group 2012 ·Journal of Neurology ·Peter Rieckmann, Alexey Boyко, Diego Centonze, Alasdair Coles, Irina Elovaara, Eva Havrdová, O. R. Hommes, Jacques LeLorier, Sarah A. Morrow, Celia Oreja‐Guevara, Nick Rijke, Sven Schippling	25
19	Cladribine as a therapeutic option in multiple sclerosis 2011 ·Clinical Immunology ·Clemens Warnke, Verena I. Leussink, Norbert Goebels, Orhan Aktaş, Alexey Boyко, Bernd C. Kieseier, Hans‐Peter Hartung	10
20	Peripheral blood leukocytes from multiple sclerosis patients are coated with factors inhibiting their chemotaxis in the presence of myelin basic protein 1993 ·Immunology Letters ·Pinegin Bv, (unknown), (unknown), Alexey Boyко, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact